The preponderance of AD drug discovery efforts has focused on strategies to lower Aβ plaque formation, largely motivated by evidence that familial AD can result from mutations in the amyloid precursor protein (APP) or the presenilin proteins found in the γ-secretase complex involved in the proteolytic cleavage of APP to yield Aβ peptides (21). The gene discussed is APP; the disease is Alzheimer disease.